A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of aPseudomonas aeruginosahybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers

Pseudomonas infection in chronic obstructive pulmonary disease

(2012) Ganapathi Iyer Parameswaran et al.   Future Microbiology

Vaccine adjuvants: The dream becomes real

(2011) Aldo Tagliabue et al.   Human vaccines & immunotherapeutics

Kinetics and Longevity of Antibody Response to Influenza A H5N1 Virus Infection in Humans

(2009) R. Kitphati et al.   Clinical and Vaccine Immunology

Population-Based Study of the Epidemiology and the Risk Factors for Pseudomonas aeruginosa Bloodstream Infection

(2009) M. D. Parkins et al.   INFECTION

Pseudomonas aeruginosa: a formidable and ever-present adversary

(2009) K.G. Kerr et al.   JOURNAL OF HOSPITAL INFECTION

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults

(2009) Wendy A. Keitel et al.   VACCINE

Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals

(2009) Charles E. Rupprecht et al.   VACCINE

Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers

(2009) Dirk Bumann et al.   VACCINE

ClpXP proteases positively regulate alginate overexpression and mucoid conversion in Pseudomonas aeruginosa

(2008) D. Qiu et al.   MICROBIOLOGY-SGM